SNPMiner Trials (Home Page)
Report for Clinical Trial NCT03581617
Developed by Shray Alag, 2020.
SNP Clinical Trial Gene
Prognostic Markers in Women With Primary Unexplained Infertility
1. Background: In women, unexplained infertility has been associated with a range of cellular and molecular defects in the endometrium, adverse immune responses and immunological factors. Natural killer (NK) cells are included as they constitute the most abundant leukocyte population in the decidua. While decidua NK cells were extensively investigated, the study of endometrial eNK cells still lacks comprehensive researches. The reduction in eNK frequency has been associated with infertility status, in particular in the presence of a concomitant herpesvirus viremia. Since herpesviruses use as immune-escape HLA-G and HLA-E molecules, that are immune-inhibitory and important for a correct placentation, they could represent infertility co-factors. 2. Aims: Since lack of an accurate diagnosis in reproductive medicine leads to treatment failure, this proposal focuses on eNK cell characterization as a diagnostic factor for unexplained women infertility. We will evaluate also co-factors, taking into consideration herpesvirus infection and HLA-G and HLA-E expression. 3. Methods: Peripheral blood and endometrial NK cells will be immune-phenotyped and cell count and activation status (CD107a, IL-6, IL-10, IL-17) will be correlated with infertility condition. The implication of herpesvirus will be evaluated by DNA from peripheral blood and endometrial flushing samples analysis by HSV-1, HSV-2, EBV, CMV, HHV-6, HHV-7, VZV and HHV-8 specific primers an PCR technique. HLA-G and HLA-E expression will be analyzed in peripheral blood and endometrial environment by flow cytometry and ELISA tests and correlated by NK cell expression of their receptors (KIRs, LILRB1/2, NKG2A). 4. Expected results: On the basis of our preliminary results, we expect to identify NK cells as prognostic marker for primary unexplained infertility, with herpesvirus infection and HLA-G and HLA-E expression as co-factors. These data will be of importance in the management of infertile women.
NCT03581617 Infertility, Female MeSH: Infertility Infertility, Female
HPO: Female infertility Infertility
5 Interventions
Name: NK cell analysis
Description: We selected to perform the study during the proliferative phase (day 9-11), where only resident eNK cells are present in the endometrium. The samples will be analyzed with the following methods, that are routinely used in the OUs of the proposal: - pNK cell analysis: PBMCs will be purified with Ficoll solution and NK cells will be analyzed by flow cytometry (FacsVantage, BD) with anti-CD56, CD16, CD9, CD49a, KIRs, LILRB1, LILRB2, CD94, CD107a eNK cell analysis: eNK cells will be obtained from endometrial biopsies during proliferative phase, determined by ultrasound scan and analyzed for NK cell subtypes and KIRs, LILRB1, LILRB2, CD94, CD107a expression by flow cytometryType: Diagnostic TestFertile women Infertile women
Name: Herpesvirus detection
Description: Herpesvirus detection: DNA will be analyzed by specific primers for HSV-1, HSV-2, EBV, CMV, HHV-6, HHV-7, VZV, and HHV-8, with PCR and nested PCRType: Diagnostic TestFertile women Infertile women
Name: sHLA-G analysis
Description: sHLA-G analysis: sHLA-G quantification in plasma and endometrial flushing will be performed by ELISA using anti-HLA-G (G233) and anti-beta2-microglobulin HRP-conjugated moAbs (Exbio)Type: Diagnostic TestFertile women Infertile women
Name: HLA-G 14bp INS/DEL typing
Description: Genomic DNA will be genotyped by RealTime PCRType: Diagnostic TestFertile women Infertile women
Name: sHLA-E analysis
Description: sHLA-E analysis: sHLA-E quantification in plasma and endometrial flushing will be performed by ELISA using anti-HLA-E (3D12, eBioscience) and anti-beta2-microglobulin HRP-conjugated moAbs (Exbio)Type: Diagnostic TestFertile women Infertile women
Primary Outcomes
Description: Percentage of (e)NK CD56brightCD16-
Measure: Prognostic value of NK cells in female idiopathic infertility Time: 20 monthsDescription: Presence of HHVs infection in endometrial cells
Measure: Herpesvirus detection Time: 16 monthsSecondary Outcomes
Description: Levels of sHLA-G and sHLA-E in uterine flushing samples
Measure: Levels of sHLA-G and sHLA-E cellule pNK e eNK Time: 16 monthsDescription: Frequency of HLA-G and HLA-E genetic polymorphisms
Measure: HLA-G and HLA-E genetic polymorphisms Time: 10 monthsDescription: Levels of Th1 and Th2 cytokines
Measure: Cytokines levels in endometrial flushing samples Time: 10 monthsTime Perspective: Prospective
Cohort
There is one SNP
SNPs
1 rs66554220
HLA-G expression is controlled by a polymorphism of insertion/deletion (ins/del) of 14 base pairs (rs66554220), where the deletion of 14bp stabilizes the mRNA producing higher levels of HLA-G (15).
We will genotype the women for rs66554220 polymorphism, to evaluate the implication in HLA-G levels of expression in infertile condition.